Frontiers in Oncology最新文献

{"title":"A long-term retrospective analysis of oncologic and fertility outcomes in cervical cancer patients undergoing radical trachelectomy.","authors":"Yu Liu, Xuyin Zhang, Weijuan Xin, Yan Ding, Yunqiang Zhang, Ning Zhang, Keqin Hua","doi":"10.3389/fonc.2025.1591923","DOIUrl":"10.3389/fonc.2025.1591923","url":null,"abstract":"<p><strong>Background: </strong>Given the excellent prognosis of early-stage cervical cancer, fertility-sparing surgery has grown as a priority, significant alternative for radical hysterectomy in women being of reproductive age. We aimed to investigate the outcomes and subsequent pregnancies of early-stage cervical cancer patients who received radical trachelectomy. Moreover, there is a scarcity of literature directly comparing the impact of whether performing cervical cerclage concurrently with radical trachelectomy on patients' reproductive outcomes.</p><p><strong>Methods: </strong>Women with IA1-IB2 cervical cancer who underwent fertility-sparing surgery at the Obstetrics and Gynecology Hospital of Fudan University were reviewed from January 2014 to May 2024.Radical trachelectomy in 70 women was performed by surgical team from the gynecologic oncologic center. Clinical characteristics, intraoperative, pathological results, oncologic, fertility and follow-up data of these patients were recorded and retrospectively analyzed. This study compared surgical and perinatal outcomes between patients who underwent cervical cerclage during radical trachelectomy (n=49) and those who did not receive the procedure simultaneously (n=21).</p><p><strong>Results: </strong>A total of 70 women (mean age: 31years) underwent radical trachelectomy (RT) of whom 68.6% were nulliparous. The FIGO stage distribution was IA1 (n=6), stage IA2 (n=7), stage IB1 (n=49), and stage IB2 (n=8). The operative duration was significantly longer in the cerclage group than in the control group (285.4±63.9 min vs 204.8±61.9 min; <i>p</i> < 0.001, 95% CI 47.51-113.48) with greater intraoperative blood loss (201.0 mL vs 170.1 mL, <i>p</i>=0.187, 95% CI -15.10-75.72). Overall, 36 women (51.4%) were seeking parenthood, and 26 succeeded (72.2%). There were 20 live births (76.9%), 12 women delivered in term (46.2%), 7 infants were born between 32 and 36+6 weeks, 1 between 28 and 31+6 weeks, all live birth. The mean neonatal birth weight was slightly lower in the cerclage group than in the control group (2625 g vs 2828.6 g; <i>p</i>=0.265, 95% CI -575.17 to 168.03). At the end of the follow-up period (median 68.7 months, range 34-153 months), one individual is currently 27+3 weeks pregnant, three patient had recurrence, and all women are alive and 20 children born to fertility-sparing surgery patients exhibited normal development.</p><p><strong>Conclusion: </strong>Radical trachelectomy provides excellent oncologic results with an outstanding fertility rate and obstetric outcome for patients with early cervical cancer. RT combined with intrauterine-cervical stent is a safe and effective fertility-sparing surgery but cervical cerclage is not recommended.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1591923"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumab-induced vanishing bile duct syndrome: a case report.","authors":"Carlos Tomás Noblejas Quiles, José Antonio Macías Cerrolaza, Javier David Benitez Fuentes, Laura López Gómez, Manuel Sánchez Cánovas, María Nevado Rodríguez, Miguel Martín Cascón, Isabel Vigueras Campuzano, Asunción Chaves Benito, Antonio David Lázaro Sánchez","doi":"10.3389/fonc.2025.1637847","DOIUrl":"10.3389/fonc.2025.1637847","url":null,"abstract":"<p><p>Vanishing bile duct syndrome (VBDS) is a rare but potentially fatal cause of intrahepatic cholestasis, usually associated with autoimmune, infectious or drug-induced etiologies. We present the first documented case of VBDS induced by Atezolizumab, an immune checkpoint inhibitor approved as adjuvant therapy in resected stage II-IIIA non-small cell lung cancer. A 63-year-old man developed cholestatic liver injury after three cycles of Atezolizumab, with progressive jaundice and elevated bilirubin despite immunosuppressive therapy. The diagnosis was confirmed by liver biopsy, which revealed intrahepatic bile duct leakage in more than 50% of the portal tracts. Despite initial stabilization, the patient's bilirubin levels continued to rise and liver transplantation was contraindicated. He was discharged with immunosuppressive and supportive treatment, under close follow-up. This case highlights the need for greater clinical awareness of rare immunotherapy-associated immune-mediated hepatotoxicities, and underlines the importance of histological confirmation in severe or atypical presentations.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1637847"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Heterotypic neutrophil-in-tumor structure: a novel pathological feature first discovered in the tissues of OPSCC.","authors":"","doi":"10.3389/fonc.2025.1699151","DOIUrl":"https://doi.org/10.3389/fonc.2025.1699151","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fonc.2022.807597.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1699151"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA to anticipate loco-regional recurrence in early-stage breast cancer: a proof-of-concept study.","authors":"Valentina Appierto, Elena Tamborini, Paola Tiberio, Adele Busico, Loris De Cecco, Marco Silvestri, Cinzia De Marco, Elena Cavadini, Maria Carmen De Santis, Secondo Folli, Gianfranco Scaperrotta, Rebecca Manitto, Andrea Vingiani, Giancarlo Pruneri, Serena Di Cosimo","doi":"10.3389/fonc.2025.1621322","DOIUrl":"10.3389/fonc.2025.1621322","url":null,"abstract":"<p><strong>Background: </strong>Loco-regional recurrence (LRR) poses a clinical challenge for the follow-up of patients treated with curative intent for early-stage breast cancer (EBC). While circulating tumor DNA (ctDNA) has been shown to predict distant metastases, its value for LRR is less characterized.</p><p><strong>Methods: </strong>Starting from an index case with documented LRR and available tumor and plasma samples, we report the analysis of the prospective phase III fenretinide prevention trial, which primarily aimed to assess the incidence of second malignancy in women with T1-T2 N0 EBC. Patients were eligible if they had FFPE and/or frozen tissue from primary or recurrent invasive tumor for next generation sequencing, and at least three serial plasma samples for ctDNA analysis by digital PCR.</p><p><strong>Results: </strong>The <i>TP53</i> R196* mutation was identified in the primary tumor of the index case with a variant allele frequency (VAF) of 29%, and in the LRR with a VAF of 58%. The same mutation was also detected in plasma prior to both the primary and LRR surgeries with VAFs of 0.19% and 0.12%, respectively. Following treatment, the mutation became undetectable in plasma samples during follow-up, consistent with the absence of recurrence. Among 40 eligible patients from the fenretinide prevention trial, 27 (67.5%) had primary tumor somatic variants trackable in plasma. Median age was 55 years (range, 35-78); stage I (16, 59%) and stage II (11, 41%); mostly luminal-like (19, 70%); median follow-up 173 months (range, 98-193); common mutations included <i>PIK3CA</i> (50%), <i>TP53</i> (30.7%), and <i>PTEN</i> (5.9%). Six patients developed LRR as first event; 4 distant metastases. In all LRR cases, except one, ctDNA was detected prior to surgery and anticipated the clinical diagnosis up to 28 months. Three patients with LRR developed distant metastases 1 to 2 years later.</p><p><strong>Conclusion: </strong>These findings show the potential of ctDNA for the early detection of LRR in EBC, and its promise as a tool for timely interventions and personalized surveillance strategies.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1621322"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: A case of carcinoma <i>in situ</i> of the bladder misdiagnosed as \"chronic prostatitis\" for a long time.","authors":"Chongbin Li, Guiyun Zhu, Jianzhen Liu, Wei Li","doi":"10.3389/fonc.2025.1632624","DOIUrl":"10.3389/fonc.2025.1632624","url":null,"abstract":"<p><strong>Background: </strong>Carcinoma <i>in situ</i> of the bladder (CIS) has no specific clinical symptoms and is easily confused with inflammatory lesions of the bladder and urethra. It is usually not considered as the primary diagnosis and requires cystoscopic biopsy to confirm the diagnosis.</p><p><strong>Case presentation: </strong>A 44-year-old male patient was diagnosed with chronic prostatitis due to \"intermittent urinary frequency, dysuria, and urethral dribbling after defecation\" and was treated with intermittent anti-infective and symptomatic therapy for 2 years, with symptoms recurring after discontinuing the medication. This patient underwent urine exfoliative cytology, which revealed exfoliated cancer cells, and proceeded to undergo cystoscopic biopsy, which did not reveal a pathologic basis for the cancer. The diagnosis of CIS was finally confirmed only after a diagnostic transurethral bladder mucosal electrodesiccation and pathologic examination. Bacillus Calmette-Guerin (BCG) bladder instillation was then performed for up to one and a half years, and the patient recovered.</p><p><strong>Conclusion: </strong>Bladder carcinoma <i>in situ</i> can present with urinary irritation symptoms similar to those of prostatitis and is therefore easily misdiagnosed as chronic prostatitis. It is recommended for patients with recurrent urinary frequency and dysuria as the main symptoms to undergo urine exfoliative cytology routinely if bladder tumor cannot be ruled out, and cystoscopy and biopsy should be performed if necessary to rule out CIS.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1632624"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glioma-neuron interactions: insights from neural plasticity.","authors":"Jingyu Feng, Jun Yang","doi":"10.3389/fonc.2025.1661897","DOIUrl":"10.3389/fonc.2025.1661897","url":null,"abstract":"<p><p>The development of gliomas is linked to neuroplasticity. Neurons, which are largely nonregenerative in adulthood, rely on axons and synapses to rebuild the neural network in response to experience and injury. Neural stem cells and immune cells coordinate \"creation\" (e.g., neurogenesis) and \"clearance\" (e.g., synaptic pruning), guided by signals from neural circuits. This review summarizes neuroplasticity mechanisms and explores their connection to gliomas, revealing that glioma cells hijack neural network derived signals to promote growth, migration, and stem-like properties, while simultaneously disrupting normal neural conduction. Similar to oligodendrocyte precursor cells (OPCs), gliomas exploit neural network regulation but are prone to uncontrolled proliferation. Moreover, glioma induced neural hyperexcitability disrupts circuit homeostasis, creating a permissive microenvironment for glioma progression. Consequently, neuroplasticity will contribute to the study of glioma related mechanisms and the development of more targeted strategies for prevention and control.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1661897"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid metastases from breast cancer: a case report and brief literature review.","authors":"Siqi He, Jicheng Li, Donglai Wang, Qiaohong Nong, Guangxin Li, Ying Yin, Xiaoling Liu","doi":"10.3389/fonc.2025.1614376","DOIUrl":"10.3389/fonc.2025.1614376","url":null,"abstract":"<p><p>Thyroid metastasis from breast cancer is a rare occurrence and often indicates a poor prognosis. We report the case of a young female patient with thyroid metastasis from breast cancer after being diagnosed with the Graves' disease, and review the clinical characteristics and diagnostic approach of thyroid metastases. The mechanism may be associated with altered microenvironment induced by the Graves' disease and Hashimoto's thyroiditis. Thyroid function and abnormal imaging examination should be paid attention during breast cancer patients' follow-up. Early identification and individualized treatment of thyroid metastasis may contribute to prolonged survival and improved quality of life.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1614376"},"PeriodicalIF":3.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Dynamic contrast-enhanced imaging: technology progress and clinical application in oncology.","authors":"Zujun Hou, Baowei Fei, Jingliang Cheng","doi":"10.3389/fonc.2025.1681143","DOIUrl":"10.3389/fonc.2025.1681143","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1681143"},"PeriodicalIF":3.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of programmed cell death ligand 1 protein and other biomarkers in patients with gastric cancer and gastroesophageal junction cancer: a retrospective single centre study in Brazil.","authors":"Jéssica Gonçalves Azevedo, Beatriz de Araujo Cortez, Maria Aparecida do Carmo Rego, Felipe Berlinski, Dominihemberg Ferreira, Angélica Carreira Dos Santos, Ana Beatriz Machado De Almeida, Paula de Mendonça Batista, Cicera Pimenta Marcelino, Fernanda Franco Munari, Iara Viana Vidigal Santana, Vinicius Duval da Silva, Guilherme Ribeiro, Gustavo Noriz Berardinelli, Diego Burgardt, Durval R Wohnrath, Rui Manuel Reis","doi":"10.3389/fonc.2025.1623264","DOIUrl":"10.3389/fonc.2025.1623264","url":null,"abstract":"<p><strong>Background: </strong>Programmed cell death ligand 1 (PD-L1) is a key prognostic biomarker that can predict response to immunotherapies in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, there is a lack of real-world data on the distribution of PD-L1 and other prognostic biomarkers among patients with GC and GEJC in Brazil.</p><p><strong>Objectives: </strong>To analyze PD-L1 expression, the microsatellite instability (MSI) and human epidermal growth factor receptor 2 (HER-2) status among patients with GC and GEJC in a Brazilian cancer hospital and to evaluate the association between PD-L1 expression and other biomarkers and clinicopathological parameters.</p><p><strong>Methods: </strong>This observational, retrospective study was conducted between March 2019 and May 2019 at the <i>Barretos Cancer Hospital</i> in Brazil. The levels of PD-L1 expression and other biomarkers were analyzed for patients whose formalin-fixed paraffin-embedded tumor tissue samples were preserved at the hospital. PD-L1 expression was measured by the immunohistochemical (IHC) method. MSI was determined by molecular assays, whereas IHC and fluorescence <i>in situ</i> hybridization (FISH) assays were conducted to evaluate HER-2 expression. The association between PD-L1 expression, MSI, HER-2-positivity, and clinicopathological parameters was determined using a chi-square test.</p><p><strong>Results: </strong>A total of 162 patients were included in the study. Most of the patients were male (65.4%), with a mean age of 61 years. PD-L1 expression (CPS ≥1) was observed in 49.4% of patients (n = 80) of patients, whereas MSI-high and HER-2 expression were reported in 12.3% (n = 20) and 8.0% (n = 13), respectively. PD-L1 expression was significantly associated with older age and MSI.</p><p><strong>Conclusion: </strong>A high prevalence of PD-L1 expression was observed among patients with GC and GEJC, but HER-2-positivity was lower than global prevalence. PD-L1 expression was associated with MSI-high status. The study outcomes can be used for the selection of appropriate therapies for patients with GC and GEJC in Brazil.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1623264"},"PeriodicalIF":3.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.","authors":"Zheng Liu, Jingsheng Cai, Yun Li, Wenhan Weng","doi":"10.3389/fonc.2025.1557097","DOIUrl":"10.3389/fonc.2025.1557097","url":null,"abstract":"<p><strong>Introduction: </strong>In the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.</p><p><strong>Methods: </strong>Resected pT1/2 PM patients were selected. The Kaplan-Meier method was applied to assess survival differences, and propensity score matching was utilized to balance baseline characteristics. Univariable and multivariable Cox analyses were conducted to determine prognostic factors. Multiple model parameters were used to evaluate the performance of the ninth and eighth edition pT staging in distinguishing between T1 and T2 patients.</p><p><strong>Results: </strong>A total of 818 eligible patients were included, among whom 325 initially classified as T1 were reclassified as T2 due to fissural invasion, resulting in 57 patients remaining with pT1 disease. Survival analyses demonstrated that both before and after matching, the ninth edition T staging effectively differentiated between T1 and T2 patients, whereas the eighth edition did not perform as satisfactorily in distinguishing between the groups. Cox regression analyses further confirmed that the ninth edition T staging was a strong prognostic factor, whereas the eighth edition T staging was not prognostic. Lastly, model parameter results indicated that the ninth edition T staging performed better in distinguishing between T1 and T2 patients compared to the eighth edition.</p><p><strong>Discussion: </strong>Our study provided validation and endorsement for the revisions implemented in the ninth edition pT staging, specifically the reclassification of patients with fissural invasion from pT1 to pT2. This research contributed to the precise staging of PM patients.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1557097"},"PeriodicalIF":3.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}